Preclinical Therapeutics Publications

Publications involving PTC participation (PTC authorship in bold)

2011

Arata-Kawai H, Singer MS, Bistrup A, Zante A, Wang YQ, Ito Y, Bao X, Hemmerich S, Fukuda M, Rosen SD. (2011) Functional contributions of N- and O-glycans to L-selectin ligands in murine and human lymphoid organs. Am J Pathol. 178(1):423-33

Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. (2011) Outgrowth of Drug-Resistant Carcinomas Expressing Markers of Tumor Aggression after Long-term T{beta}RI/II Kinase Inhibition with LY2109761. Cancer Res. 71(6):2339-49.

Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. (2011). Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse. Cancer Res. 71(11):3863-71.

2010

Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 7;2(16):16ra7.

Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. (2010) Tumor detection by imaging proteolytic activity. Cancer Res. 70(4):1505-12.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. (2010) Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 141(1):13-21.

Erez N, Truitt M, Olson P, Arron ST, Hanahan D. (2010). Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell. 17:135-47.

Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. (2010). Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 17:249-61.

2009

Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. (2009) MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 29(5):1071-9.

Bouchard LS, Anwar MS, Liu GL, Hann B, Xie ZH, Gray JW, Wang X, Pines A, Chen FF. (2009) Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci USA. 106(11):4085-9.

Dumont N, Crawford YG, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring GC, Turashvili G, Aparicio S, Gauthier ML, Fordyce CA, McDermott KM, Tlsty TD. (2009) Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res.;11(6):R87.

Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, Hann B, Diamond MI. (2009) Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA. 106(17):7233-8.

Murphy PA, Lu G, Shiah S, Bollen AW, Wang RA. Endothelial Notch signaling is upregulated in human brain arteriovenous malformations and a mouse model of the disease. (2009). Lab Invest. 89:971-82.

Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. (2009). MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009. 23:2152-65.

Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. (2009) Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 15(7):2311-22.

2008

Kang, J.S., Saunier, E.F., Akhurst, R.J. and Derynck, R. (2008) The type I TGF-β receptor is covalently modified and regulated by sumoylation. Nature Cell Biology 10(6):654-64.

Murphy PA, Lam MT, Wu X, Kim TN, Vartanian SM, Bollen AW, Carlson TR, Wang RA. (2008). Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci USA. 105:10901-6.

Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW. (2008) Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 8(9):2851-7.

2007

Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. (2007). A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21:379-84.

Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC. (2007). Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol. 71:1525-34

Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. (2007). Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy., J Magn Reson Imaging. 26(6):1618-25.

Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445(7126), 437-4

2006

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006 Mar 15;66(6):3271-7.

Goldkorn A, Blackburn EH. (2006). Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 66:5763-71.

Kirpotin DB, Drummond DC, Hong K, Shao Y, Shalaby R, Nielsen UB, Marks JD, Benz CC, and Park JW. Antibody targeting of long circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66(13)6732-40.

Mao, J-H., Saunier, E.F., de Koning, J., McKinnon, M.M., Higgins, M.N., Nicklas, K., Yang, H-T., Balmain, A. and Akhurst, R.J. (2006). Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc. Natl. Acad. Sci (USA) 103(21):8125-30.

Marx, C, Berger C,1 Xu, F, Amend, C, Johnson, J, Scott, GK, Hann, B, Park, JW, and Benz, CC. (2006). Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription., Assay and Drug Development Technologies, 4, 273-84.

2005

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Park JW, Kirpotin DB, and Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res. 2005, 11(9):3392-401

Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2005 Oct; 22(4):511-9.

Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005 Dec 15; 65(24):11631-8.

Additional Resources
A searchable database of core facilities at all UCSF campus locations, provided by the Clinical and Translational Science Institute at UCSF, is available here.